JPWO2023008461A5 - - Google Patents

Info

Publication number
JPWO2023008461A5
JPWO2023008461A5 JP2022554213A JP2022554213A JPWO2023008461A5 JP WO2023008461 A5 JPWO2023008461 A5 JP WO2023008461A5 JP 2022554213 A JP2022554213 A JP 2022554213A JP 2022554213 A JP2022554213 A JP 2022554213A JP WO2023008461 A5 JPWO2023008461 A5 JP WO2023008461A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554213A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023008461A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/028877 external-priority patent/WO2023008461A1/ja
Publication of JPWO2023008461A1 publication Critical patent/JPWO2023008461A1/ja
Publication of JPWO2023008461A5 publication Critical patent/JPWO2023008461A5/ja
Pending legal-status Critical Current

Links

JP2022554213A 2021-07-27 2022-07-27 Pending JPWO2023008461A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021122071 2021-07-27
PCT/JP2022/028877 WO2023008461A1 (ja) 2021-07-27 2022-07-27 癌の治療及び/又は予防のための医薬品

Publications (2)

Publication Number Publication Date
JPWO2023008461A1 JPWO2023008461A1 (https=) 2023-02-02
JPWO2023008461A5 true JPWO2023008461A5 (https=) 2025-07-25

Family

ID=85087718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554213A Pending JPWO2023008461A1 (https=) 2021-07-27 2022-07-27

Country Status (9)

Country Link
US (1) US20250325663A1 (https=)
EP (1) EP4378477A4 (https=)
JP (1) JPWO2023008461A1 (https=)
KR (1) KR20240042415A (https=)
CN (1) CN117651566A (https=)
AU (1) AU2022316644A1 (https=)
CA (1) CA3227703A1 (https=)
MX (1) MX2024001099A (https=)
WO (1) WO2023008461A1 (https=)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス,インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
ES2739612T3 (es) * 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN107408520B (zh) 2015-03-03 2022-02-25 卢茨·瑞布斯道克 检查系统
AU2019242520B2 (en) * 2018-03-30 2026-02-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CA3175137A1 (en) * 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer

Similar Documents

Publication Publication Date Title
JP2025092589A5 (https=)
JP2017048240A5 (https=)
JP2018070648A5 (https=)
JP2019535250A5 (https=)
RU2009115363A (ru) Антагонисты рецепторов для лечения метастатического рака
JP2020522486A5 (https=)
RU2013136172A (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
JP2020514310A5 (https=)
JP2018508483A5 (https=)
JP2014530215A5 (https=)
JP2018529312A5 (https=)
HRP20180262T1 (hr) Monoklonska anti-gt468 protutijela za liječenje karcinoma
JP2021513541A5 (https=)
JP2018503365A5 (https=)
RU2017105915A (ru) Антитела против pd-1
JP2010531140A5 (https=)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
FI3941946T3 (fi) Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja
JP2021531255A5 (https=)
JP2021522347A5 (https=)
JP2025507817A5 (https=)
JP2024512574A5 (https=)
JP2020517725A5 (https=)
JPWO2022270524A5 (https=)
RU2018124601A (ru) АНТИТЕЛО К Myl9